EMA is reminding healthcare professionals to closely monitor patients with COVID-19 who are receiving chloroquine or hydroxychloroquine, given the serious side effects that can result from treatment with these medicines.
The study will draw a comparison between the impact of Hydroxychloroquine and Ashwagandha for the prophylaxes against SARS-COV-2 in the health care providers with increased risk during the COVID-19 Pandemic.